AzTrials
AzTrials

Cardiac ArrestAfterROSC2NCT05606809

Comparison of Scores for Early Brain Damage Assessment at Intensive Care Unit Admission After Cardiac Arrest

An observational study of Cardiac Arrest, run by AfterROSC at 5 sites in France.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Even in patients with successful return of spontaneous circulation (ROSC), outcome after cardiac arrest remains poor. The overall in-hospital survival rate widely varies both worldwide and across communities, from 1 to 4 folds according to circumstances of arrest and post-resuscitation interventions. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Cardiac Arrest
What is being tested?
Calculation of early prognosis score
How many people
4,500 participants
Where
5 sitesFrance
Study dates
2 Nov 2022to 31 Dec 2027
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: This is an observational, prospective, multicentric prognostic study. The study period is 3 years, and investigators plan to include 4500 patients in 20 ICUs in France. For all patients included, medical history, clinical data, paraclinical results and outcome (at hospital discharge and at 3 months, including modified Rankin score) will be prospectively collected by local investigator, according to an electronical CRF.

Who may be able to join

  • all adult patients, major, admitted to intensive care after cardiac arrest (after both in and out-of hospital cardiac arrest),
  • comatose (defined by Glasgow score ≤ 8) on admission,

Who cannot join

  • cardiac arrest occurring intra-hospital,
  • minor patient,
  • major patient under guardianship,
  • protected persons,
  • prior inclusion in the study

Trial locations and contacts

5 sites in 1 country. Contact the study team or a site near you to ask about taking part.

Jean Baptiste Lascarrou, MD, PhD contact

+33240087376

jeanbaptiste.lascarrou@chu-nantes.fr

Alain Cariou, MD, PhD contact

alain.cariou@aphp.fr

5 sites in 1 country

France5 sites, 5 recruiting
  • Hopital Jacques Cartier

    Massy

    Wulfran Bougouin, wulfran.bougouin@gmail.com

    Recruiting
  • CHU Nantes

    Nantes, Pays de Loire

    Jean Baptiste Lascarrou, jeanbaptiste.lascarrou@chu-nantes.fr

    Recruiting
  • Clinique Ambroise Paré

    Neuilly-sur-Seine

    Guillaume Geri, ggeri92@gmail.com

    Recruiting
  • APHP, Cochin

    Paris

    Alain Cariou, alain.cariou@aphp.fr

    Recruiting
  • CH Versailles

    Versailles

    Marine Paul, mpaul@ch-versailles.fr

    Recruiting

Other trials in France

About this study

Even in patients with successful return of spontaneous circulation (ROSC), outcome after cardiac arrest remains poor. The overall in-hospital survival rate widely varies both worldwide and across communities, from 1 to 4 folds according to circumstances of arrest and post-resuscitation interventions. Several studies have already shown that early interventions performed after ROSC, such as treatment of the cause, targeted temperature management, optimal hemodynamic management and extra-corporeal life support in selected patients, could improve the outcome in post-cardiac arrest patients. However, the decision process regarding the allocation of these resources, in parallel with the management of patients' proxies, remains a complex challenge for physicians facing these situations. Consequently, several prediction models and scores have been developed in order to stratify the risk of unfavorable outcome and to discriminate the best candidates for post-resuscitation interventions. Overall, several scores exist, but external validation are lacking and direct comparisons are needed to assess relative interest of scoring systems. Indeed, establishing the optimal scoring system is crucial, for optimal treatment allocation and appropriate information to relatives.

Conditions
Cardiac Arrest
Being tested
Calculation of early prognosis score
Keywords
cardiac arrest, intensive care unit, mechanical ventilation
Medical subject headings
Heart Arrest

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Calculation of early prognosis scoreDiagnostic test

    Early prognosis score will be calculated at intensive care unit admission for each patient based on clinical and biological values as required

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Determination of Area Under Curve of Cerebral Admission Hospital Prognosis (CAHP) Score at intensive care unit admission

    Determination of AUC for CAHP score as compare to Utstein style criteria.

    CAHP score range from 0 to 300 with higher score indicates poorer prognosis

    Measured: Intensive Care Unit Admission (Usually 3 hours after cardiac arrest

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted7 Nov 2022
  2. Study start2 Nov 2022
  3. Primary completion30 Sep 2027 (estimated)
  4. Study completion31 Dec 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
4,500 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05606809
Sponsor's protocol ID
2022-A01811-42
Acronym
AfterROSC2
Status last verified
Nov 2026
First submitted
31 Oct 2022
Last updated
4 Nov 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided: Sharing of IPD will be possible upon request to steering committee of the AfterROSC Network after approval of the project by ethics committee.

Questions about this trial

What is this clinical trial studying?

An observational study of Cardiac Arrest, run by AfterROSC at 5 sites in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 4 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 5 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Jean Baptiste Lascarrou, MD, PhD (+33240087376, jeanbaptiste.lascarrou@chu-nantes.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Determination of Area Under Curve of Cerebral Admission Hospital Prognosis (CAHP) Score at intensive care unit admission (time frame: Intensive Care Unit Admission (Usually 3 hours after cardiac arrest). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Nov 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in